163 related articles for article (PubMed ID: 38280045)
1. Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma.
Versluis JM; Hoefsmit EP; Shehwana H; Dimitriadis P; Sanders J; Broeks A; Blank CU
Cancer Immunol Immunother; 2024 Jan; 73(2):28. PubMed ID: 38280045
[TBL] [Abstract][Full Text] [Related]
2. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract][Full Text] [Related]
3. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study.
Liu R; Yang F; Yin JY; Liu YZ; Zhang W; Zhou HH
Front Immunol; 2021; 12():685370. PubMed ID: 34220837
[TBL] [Abstract][Full Text] [Related]
4. 9-Gene Signature Correlated With CD8
Yan K; Lu Y; Yan Z; Wang Y
Front Immunol; 2021; 12():622563. PubMed ID: 34220795
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.
Martins Nascentes Melo L; Herrera-Rios D; Hinze D; Löffek S; Oezel I; Turiello R; Klein J; Leonardelli S; Westedt IV; Al-Matary Y; Egea-Rodriguez S; Brenzel A; Bau M; Sucker A; Hadaschik E; Wirsdörfer F; Hanenberg H; Uhlenbrock N; Rauh D; Poźniak J; Rambow F; Marine JC; Effern M; Glodde N; Schadendorf D; Jablonska J; Hölzel M; Helfrich I
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028818
[TBL] [Abstract][Full Text] [Related]
6. Multifunctionality of CD8
Manabe K; Yamasaki O; Nakagawa Y; Miyake T; Udono H; Morizane S
J Dermatol; 2021 Aug; 48(8):1186-1192. PubMed ID: 33890340
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
[TBL] [Abstract][Full Text] [Related]
8. Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors.
Fenton SE; Zannikou M; Ilut L; Fischietti M; Ji C; Oku CV; Horvath CM; Le Poole IC; Bosenberg M; Bartom ET; Kocherginsky M; Platanias LC; Saleiro D
Mol Cancer Res; 2023 Apr; 21(4):332-344. PubMed ID: 36573964
[TBL] [Abstract][Full Text] [Related]
9.
Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
Jessurun CAC; Vos JAM; Limpens J; Luiten RM
Front Oncol; 2017; 7():233. PubMed ID: 29034210
[TBL] [Abstract][Full Text] [Related]
11. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
12. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
13.
Zhou S; Zhang S; Zheng K; Li Z; Hu E; Mu Y; Mai J; Zhao A; Zhao Z; Li F
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302417
[TBL] [Abstract][Full Text] [Related]
14. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
15. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
[TBL] [Abstract][Full Text] [Related]
16. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
Front Immunol; 2021; 12():798474. PubMed ID: 35087523
[TBL] [Abstract][Full Text] [Related]
17. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Morrison C; Pabla S; Conroy JM; Nesline MK; Glenn ST; Dressman D; Papanicolau-Sengos A; Burgher B; Andreas J; Giamo V; Qin M; Wang Y; Lenzo FL; Omilian A; Bshara W; Zibelman M; Ghatalia P; Dragnev K; Shirai K; Madden KG; Tafe LJ; Shah N; Kasuganti D; de la Cruz-Merino L; Araujo I; Saenger Y; Bogardus M; Villalona-Calero M; Diaz Z; Day R; Eisenberg M; Anderson SM; Puzanov I; Galluzzi L; Gardner M; Ernstoff MS
J Immunother Cancer; 2018 May; 6(1):32. PubMed ID: 29743104
[TBL] [Abstract][Full Text] [Related]
18. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract][Full Text] [Related]
19. Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature.
Aragaki AK; Jing Y; Hoffman-Censits J; Choi W; Hahn NM; Trock BJ; McConkey DJ; Johnson BA
Eur Urol Oncol; 2022 Jun; 5(3):338-346. PubMed ID: 34426176
[TBL] [Abstract][Full Text] [Related]
20. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
